GERD & NERD Treatment Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

GERD & NERD Treatment Market Summary
Introduction to the GERD & NERD Treatment Industry
Gastroesophageal Reflux Disease (GERD) and Non-Erosive Reflux Disease (NERD) treatments encompass pharmaceuticals like proton pump inhibitors (PPIs, 75–80% of the market) and H2 receptor blockers to manage acid reflux symptoms. The market is driven by hospitals and clinics (50–60%) and drugstores (40–45%), with PPIs like Haleon’s and AstraZeneca’s leading due to efficacy. Haleon, formed in 2022 from GSK’s consumer health unit, focuses on over-the-counter solutions. The industry is moderately concentrated, with Takeda and AstraZeneca leading prescription drugs. Innovations target long-acting PPIs and non-drug therapies. Challenges include generic competition, side effect concerns, and regulatory scrutiny, yet rising GERD prevalence drives growth.

Market Size and Growth Forecast
The global GERD & NERD Treatment market is projected to reach USD 7.5–8.5 billion by 2025, with an estimated compound annual growth rate (CAGR) of 2% to 3% through 2030. Growth is driven by aging populations and lifestyle-related GERD cases.

Regional Analysis
North America holds 35–40%, with a growth rate of 2%–3%. The U.S. leads in hospital treatments, with Canada focusing on drugstores. Trends include OTC adoption.
Asia Pacific accounts for 25–30%, with a growth rate of 3%–4%. Japan’s Eisai and India’s Dr. Reddy’s drive drugstore sales. Trends focus on generics.
Europe holds 30–35%, with a growth rate of 2%–3%. Germany’s STADA focuses on PPIs. Trends include non-drug therapies.
Middle East and Africa hold 2–3%, with a growth rate of 1%–2%. The UAE’s hospitals grow, but access lags. Trends include affordability.
South America accounts for 1–2%, with a growth rate of 1%–2%. Brazil’s drugstores support demand. Trends focus on generics.

Application Analysis
Hospitals & Clinics: Holds 50–60%, with a growth rate of 2%–3%. Takeda’s PPIs dominate hospital prescriptions. Trends include combination therapies.
Drugstore: Accounts for 40–45%, with a growth rate of 2.5%–3.5%. Haleon’s OTC solutions lead. Trends focus on self-medication.
Research Centers: Holds 0–1%, with a growth rate of 1%–2%. AbbVie’s trials grow. Trends include novel drugs.
Others: Accounts for 0–1%, with a growth rate of 1%–2%. Niche therapies grow with Sandoz’s offerings.

Type Analysis
Proton Pump Inhibitors: Holds 75–80%, with a growth rate of 2%–3%. AstraZeneca’s PPIs lead. Trends include long-acting formulations.
H2 Receptor Blocker: Accounts for 5–10%, with a growth rate of 1%–2%. Teva’s blockers grow. Trends focus on affordability.
Petroleum Cracking Method (Antacids): Holds 10–15%, with a growth rate of 1.5%–2.5%. Haleon’s antacids lead. Trends include fast-acting solutions.
Others: Accounts for 1–3%, with a growth rate of 1%–2%. Novel therapies grow with Eisai’s offerings.

Key Market Players
Takeda Pharmaceutical: A Japanese firm, Takeda develops PPIs for hospitals.
AstraZeneca: A UK company, AstraZeneca focuses on PPIs for clinics.
Haleon: A UK firm, Haleon supplies OTC antacids.
Teva Pharmaceutical: An Israeli company, Teva develops H2 blockers.
Eisai: A Japanese firm, Eisai focuses on novel therapies.
Aurobindo Pharma: An Indian company, Aurobindo supplies generics.
Dr. Reddy’s Laboratories: An Indian firm, Dr. Reddy’s develops PPIs.
STADA: A German company, STADA focuses on OTC PPIs.
AbbVie: A U.S. firm, AbbVie supplies hospital therapies.
Johnson & Johnson: A U.S. company, Johnson & Johnson develops antacids.
Sandoz: A Swiss firm, Sandoz focuses on generics.
Viatris: A U.S. company, Viatris supplies H2 blockers.

Porter’s Five Forces Analysis
Threat of New Entrants: Low. Regulatory barriers deter entry, with AstraZeneca dominating.
Threat of Substitutes: Moderate. Non-drug therapies compete, but Takeda’s PPIs retain efficacy.
Bargaining Power of Buyers: High. Pharmacies switch suppliers, pressuring Haleon for pricing.
Bargaining Power of Suppliers: Low. API suppliers have limited influence, with Teva’s scale reducing dependency.
Competitive Rivalry: High. AstraZeneca and Takeda compete on efficacy and pricing.

Market Opportunities and Challenges
Opportunities
Aging Population: GERD prevalence boosts Takeda’s sales.
OTC Growth: Self-medication drives Haleon’s expansion.
Generic Expansion: India’s demand favors Dr. Reddy’s growth.
Emerging Markets: Brazil’s drugstores support Aurobindo’s share.
Novel Therapies: Non-drug solutions boost Eisai’s adoption.
Hospital Demand: Combination therapies favor AbbVie’s growth.
Lifestyle Trends: Dietary habits enhance STADA’s revenue.
Challenges
Generic Competition: Low-cost drugs pressure AstraZeneca’s margins.
Side Effect Concerns: PPI risks affect Takeda’s adoption.
Regulatory Scrutiny: Approvals slow Haleon’s innovation.
Market Saturation: Mature markets challenge Dr. Reddy’s expansion.
Supply Chain Issues: API delays disrupt Aurobindo’s delivery.
Non-Drug Therapies: Lifestyle changes threaten Eisai’s share.
Pricing Pressures: Reimbursement cuts affect STADA’s profitability.